Paper Details

  1. Home
  2. Paper Details

[Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders].

Author: HirabayashiN, HottaT, KatoY, KoderaY, MizunoH, MorishimaY, MorishitaY, SaitoH, SuzukiH, TanakaM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Imipenem/cilastatin sodium with amikacin sulfate was effective in treating severe infections complicating hematological disorders, with an overall rate of effectiveness of 61.3%. Side effects were observed in 9 patients and disappeared after completion of therapy.
Paper Details　
Original Abstract of the Article :
Imipenem/cilastatin sodium (IPM/CS) and amikacin sulfate (AMK) were administered to 111 patients with severe infections complicating hematological disorders. Of the 111 patients, 93 were included in the present analysis of efficacy and 108 in that of safety. Twenty patients were evaluated as excelle...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1880931

データ提供：米国国立医学図書館（NLM）

Imipenem/Cilastatin Sodium Plus Amikacin Sulfate for Severe Infections in Hematological Disorders

This study delves into the intricate world of [severe infections] in patients with [hematological disorders], a challenging landscape akin to a desert ravaged by a storm. The researchers investigate the effectiveness of a combination therapy, [Imipenem/Cilastatin sodium (IPM/CS) and amikacin sulfate (AMK)], hoping to find a lifeline for patients battling these infections. The findings suggest that this combination therapy might be a valuable weapon in the fight against these infections, offering a potential oasis in a perilous desert.

IPM/CS and AMK Show Promise for Severe Infections

The study found that [the combination of IPM/CS and AMK is effective in treating severe infections complicating hematological disorders]. This discovery is like finding a source of clean water in a desert wasteland, offering a much-needed solution for patients struggling with these infections.

Potential Benefits for Patients with Hematological Disorders

This research provides a potential ray of hope for patients with hematological disorders who are prone to severe infections. The combination therapy explored in this study could potentially offer a more effective treatment option, improving their chances of recovery and survival. It's like finding a sanctuary in a desert, offering a safe haven from the dangers of infections.

Dr.Camel's Conclusion

This study sheds light on a potential treatment strategy for severe infections complicating hematological disorders. The combination therapy of IPM/CS and AMK could provide a crucial lifeline for these patients, offering hope for better treatment outcomes and survival. The study is like a beacon in a storm, guiding healthcare professionals towards a more effective approach to battling these challenging infections.

Date :
  1. Date Completed 1991-09-30
  2. Date Revised 2016-11-16
Further Info :

Pubmed ID

1880931

DOI: Digital Object Identifier

1880931

SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.